R&D & Product Pipeline

Product Development – Designing and Testing Novel Drugs.

With the cell biology confirming the importance of the target well established, the next step was to hit that target with a drug that would inhibit Id, and prevent the process of tumor cell proliferation and new blood vessel formation, thereby impeding their spread.  Doing so required the creation of a company to complete the medicinal chemistry and preclinical development. Commercializing the concept required raising seed capital, organizing a team with the expertise to identify the target’s molecular structure, conducting high through-put screening and rational drug design modeling, securing the intellectual property protecting its findings and conducting the pre-clinical experiments with the most active “hits.” We were created for that purpose, and focused on developing this platform technology into the first Id-inhibitor drug. AngioGenex has accomplished key benchmarks since its inception by incubating the technology, and concretizing the concept in the form of active proprietary chemical compounds, small molecules that include our lead drug candidate AGX51 and a number of other proprietary small molecules that have shown specific activity in various animal models of various cancers and macular degeneration. Focusing on the exact three-dimensional atomic structure of the Id protein, AngioGenex chemists designed drugs that bind to the Id proteins and inhibit their activity, as validated both in the test tube and mouse models of breast cancer and macular degeneration. In accepted pre-clinical models AGX51 and its analogs can reproduce the profound impact of Id gene deletion by preventing the Id proteins from performing their role in support of the establishment and spread of cancer as they evidently interfere with Id activity both in the tumor cells themselves and the vessels that support their growth.  This dual activity is likely responsible for the superior performance of AGX51 over other drugs which only inhibit blood vessel growth.




Current Research Focus and Long Term Plan. 

AngioGenex  is subjecting  its lead compound for macular degeneration to further testing against the industry standard while it begins further testing including for safety in animals to obtain data for an IND to the FDA for eventual human clinical trials for the treatment of age related macular degeneration.  These additional tests required to complete the FDA IND requirements will require funding either from investors or through a joint venture, partnership or licensing agreement with another company. On the cancer front, the Company continues to test its lead cancer drug in various forms of cancer and has prepared a plan to conduct all necessary pre-IND work and a human clinical trial in Breast Cancer. Next, the plan is for human clinical studies to be conducted first in normal volunteers and then in cancer patients to obtain preliminary results regarding the safety and efficacy of the drug (Phase I & II). If the results of both the animal and clinical studies indicate that the drug has potential as an anti-cancer agent, the Company will attempt to identify a partner willing to assume financial responsibility while sharing later stage (Phase III) clinical development responsibility for completing the requirements for an NDA (New Drug Application) and marketing.

The Company has exclusive unencumbered ownership to the patented pharmaceutical drug that it is developing. As it makes new discoveries and develops additional data regarding its novel platform technology, biological agents and related intellectual property, the Company retains outside patent counsel and continues to thoroughly protect and defend its interest in these proprietary assets.

© 2017 Angiogenex. All rights reserved.